Event Highlights 2019
Inflammasome Therapeutics Summit
Post-Event Report 2019
Summary Of Key Findings From The Inaugural Inflammasome Therapeutics Summit | Boston 2019
The inaugural Inflamamsome Therapeutics Summit made its debut in Boston this October 29-31, 2019. The conference was a huge success with over 150 attendees in the room from over 70 organizations.
Over 3 days, expert speakers delivered thought-provoking sessions, covering the biology of the inflammasome, assessing preclinical animal models and benchmarking the specific diseases the inflammasome can target. This meeting provides delegates with valuable learning and networking opportunity for the inflammasome community. This report summarises some of the key findings from the event.
Exclusive Speaker Interview: Matt Cooper
Chief Executive Officer & Co-Founder
Inflammasome Therapeutics Summit speaker faculty
What do you believe to be the biggest challenges that inflammasome developers are currently facing?
Proof of concept in the appropriate clinical indication(s). There are thousands of scientific papers describing animal model efficacy and target validation for inflammasomes. Together, they implicate a putative causal role for inflammasome activation in disease, but it is not known if these findings will translate to humans. Although blocking IL-1β has been validated in some human diseases, inhibiting NLRP3 may be different as it will also suppress downstream IL-18 and pyroptosis (lytic cell death) while leaving the biological activity of other inflammasome members intact to fight infection...